CTOs on the Move

Avalo Therapeutics Inc

www.avalotx.com

 
Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.avalotx.com
  • 1500 Liberty Ridge Drive Suite 321
    Wayne, PA USA 19087
  • Phone: 610.254.4201

Executives

Name Title Contact Details

Funding

Avalo Therapeutics Inc raised $20M on 06/07/2021

Similar Companies

Promab Biotechnologies

Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hinsdale Hematology-Oncology Associates

Hinsdale Hematology-Oncology Associates is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CytomX

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.

Myriad RBM

Myriad RBM is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dermavant

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients` lives. The patient is at the heart of everything we do.